In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocular Therapeutix Inc. (NASDAQ:OCUL) that Jennison Associates Llc. has picked up 1,985,496 of common stock as of 2017-07-10.
The acquisition brings the aggregate amount owned by Jennison Associates Llc. to a total of 1,985,496 representing a 6.8% stake in the company.
For those not familiar with the company, Ocular Therapeutix, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapies for diseases and conditions of the eye using its hydrogel platform technology. The Company’s bioresorbable hydrogel based product candidates are designed to provide sustained delivery of therapeutic agents to the eye. Its lead product candidates are DEXTENZA (dexamethasone insert), for the treatment of post-surgical ocular inflammation and pain, allergic conjunctivitis and dry eye disease, and OTX-TP, for the treatment of glaucoma and ocular hypertension, which are extended-delivery, drug-eluting inserts that are placed into the canaliculus through a natural opening called the punctum located in the inner portion of the eyelid near the nose. It also has an intravitreal hydrogel depot, which is in preclinical development for the treatment of diseases and conditions of the back of the eye, including wet age-related macular degeneration (wet AMD).
A glance at Ocular Therapeutix Inc. (NASDAQ:OCUL)’s key stats reveals a current market capitalization of $205.06 Million based on $29.03 Million shares outstanding and a price at last close of $7.76 per share.
Looking at insider activity, there are a few transactions worth noting.
Specifically, on 2016-12-15, Sawhney picked up 45,300 at a purchase price of $7.85. This brings their total holding to 677,390 as of the date of the filing.
On the sell side, the most recent transaction saw Fortune unload 9,470 shares at a sale price of $17.16. This brings their total holding to 112,060.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Ocular Therapeutix Inc. (NASDAQ:OCUL)as things move forward to see if its progress aligns with these transactions.
Subscribe below and we’ll keep you on top of what’s happening before it moves markets.